With an annual production of 20,000 units of the nanomedicine Sina Doxosome, the company has not only introduced a new horizon in cancer treatment but has also significantly reduced the country’s reliance on imported drugs.

One of the remarkable achievements of nanotechnology is the development of various nanomedicines for managing and treating cancer patients. One such medicine is Sina Doxosome. Previously, a similar drug was produced by an American company and sold at a significantly higher price. Now, thanks to the efforts of experts at this knowledge-based company, a novel and more cost-effective version is available to the medical community in the country. Leveraging advanced nanotechnology, Exir Nano Sina has successfully developed a domestic version of this drug.

The CEO of Exir Nano Sina emphasized the significant role of Sina Doxosome as an anti-tumor drug in treating specific types of cancer. He stated: “This drug is used in the treatment of metastatic breast cancer, especially for patients who are at risk of heart complications due to their medical history or risk factors. Additionally, Sina Doxosome is effective in the treatment of advanced ovarian cancer, serving as a crucial therapeutic option to reduce the growth and spread of cancer cells.”

He further added: “This drug is also an effective solution for treating Kaposi's sarcoma in AIDS patients. It contains a drug capable of selectively destroying cancer cells. The hydrochloride doxorubicin in this drug is encapsulated in small liposomal spherical shells.”

Highlighting the innovative concentration process used in the drug, Pourahadi explained: “This process allows the drug to more effectively target cancerous tissues via the bloodstream. This innovation brings new hope to cancer patients, especially those with AIDS, by providing them with an efficient treatment option with fewer side effects.”

Pourahadi also noted that the research and technological studies for developing this drug began over a decade ago by a team of academic specialists within the company. He stated: “These efforts were pursued with perseverance and determination despite strict Ministry of Health regulations and challenges related to obtaining approvals. We have now secured all the necessary certifications.”

Regarding the administration guidelines for this medicine, he explained: “Sina Doxosome is administered via intravenous infusion, and its appropriate dosage varies based on the type of treatment and the patient’s condition. For breast and ovarian cancer treatment, a dose of 50 milligrams every four weeks is generally recommended.”

On the production capacity of the company, the CEO remarked:“Annually, 20,000 units of Sina Doxosome are produced, fully meeting the domestic demand.”

7,000 Iranian Nanomedicines to Be Exported to Iraq Soon
Discussing recent achievements, the CEO noted: “This knowledge-based product goes beyond merely meeting domestic needs. Our primary goal is to establish the brand of Iranian nanomedicines in global markets and compete with similar international products.”
He further announced the company’s export successes: “We have already exported this drug to Syria, and plans are in place to export 7,000 units of this nanomedicine to Iraq by the end of this year.”

Less Than One-Tenth the Price of Imported Alternatives
Pourahadi concluded by emphasizing the competitive pricing of nanomedicines:“The global version of this drug costs $65, whereas the domestic version is priced at approximately $17 (excluding insurance tariffs). This level of production not only meets the needs of cancer patients but also reduces the country’s reliance on imported medicines, resulting in significant foreign currency savings.”